Q1 Earnings Estimate for SYRS Issued By HC Wainwright

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – HC Wainwright issued their Q1 2025 earnings per share estimates for Syros Pharmaceuticals in a report issued on Wednesday, November 13th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.70) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.68) EPS and Q4 2025 earnings at ($0.69) EPS.

Other research analysts have also issued reports about the stock. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. StockNews.com cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. Finally, Piper Sandler reiterated an “overweight” rating and set a $5.00 target price (down from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Price Performance

SYRS stock opened at $0.26 on Friday. The firm has a 50 day moving average of $1.99 and a 200-day moving average of $3.75. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97. The firm has a market capitalization of $6.96 million, a P/E ratio of -0.09 and a beta of 1.59. Syros Pharmaceuticals has a 12 month low of $0.25 and a 12 month high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same period in the prior year, the company posted ($1.35) earnings per share.

Insider Buying and Selling

In related news, CEO Conley Chee acquired 50,000 shares of Syros Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The shares were purchased at an average cost of $1.51 per share, with a total value of $75,500.00. Following the completion of the purchase, the chief executive officer now owns 72,504 shares of the company’s stock, valued at $109,481.04. This represents a 222.18 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jason Haas bought 45,344 shares of the stock in a transaction dated Thursday, September 12th. The stock was bought at an average cost of $1.68 per share, with a total value of $76,177.92. Following the purchase, the chief financial officer now owns 124,552 shares in the company, valued at $209,247.36. The trade was a 57.25 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 130,707 shares of company stock worth $206,491 in the last quarter. 12.26% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new position in Syros Pharmaceuticals during the 3rd quarter valued at about $34,000. Virtu Financial LLC purchased a new position in shares of Syros Pharmaceuticals during the first quarter valued at approximately $64,000. Acadian Asset Management LLC bought a new position in shares of Syros Pharmaceuticals during the first quarter valued at approximately $91,000. Certuity LLC purchased a new stake in Syros Pharmaceuticals in the second quarter worth $109,000. Finally, Kennedy Capital Management LLC bought a new stake in Syros Pharmaceuticals in the first quarter valued at $2,166,000. 91.47% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.